Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nu Eyne M02 in Early to Moderate Dry AMD
NCT05259371Recruiting
- Sponsor
- Nu Eyne
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial in age-related macular degeneration (AMD), sponsored by Nu Eyne. Primary endpoint: Number of Safety Events at 16 weeks. Started Oct 2022; status: recruiting.
02
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT05259371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259371.